THE ADDED VALUE OF 166HO TRANS-ARTERIAL RADIOEMBOLIZATION TO SYSTEMIC THERAPY IN LIVER METASTATIC BREAST CANCER PATIENTS - Radioembolistation and chemotherapy in liver metastatic breast cancer

开始日期2023-10-19

申办/合作机构-

NCT05550090 / RecruitingN/AIIT

Clinical Study of Dynamic Contrast-enhanced Magnetic Resonance Imaging Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver Metastasis of Breast Cance

The purpose of this study is to further use DCE-MRI and ivim-dwi to predict the chemotherapy sensitivity of liver metastasis of breast cancer at an early stage, and to predict the treatment response of tumor at an early stage by using the changes of their functional parameters, and to compare the efficacy and advantages of IVIM functional parameters and DCE-MRI parameters in predicting the efficacy.To explore the efficacy of "perfusion" and "diffusion" parameters of magnetic resonance imaging as "biomarkers" for early prediction of chemotherapy response and prognosis of breast cancer patients with liver metastasis. And to provide guidance for optimizing the clinical treatment scheme of breast cancer patients with liver metastasis.
At the same time, this study will use the method of artificial intelligence to deeply mine the images, and further find out the indicators for early prediction of the therapeutic effect of liver metastasis of breast cancer.

开始日期2022-09-16

申办/合作机构

浙江省肿瘤医院

NCT05315687 / Withdrawn临床2期IIT

Safety and Efficacy of Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

This phase II trial studies the effects of radioembolization with yttrium Y-90 works as a 2nd or 3rd line therapy for treating patients with breast cancer that has spread to the liver (metastatic to the liver). Yttrium Y-90 radioembolization is a therapy that injects radioactive particles directly into an artery that feeds liver tumors to cut off their blood supply.

开始日期2022-08-17

申办/合作机构

Emory University

[+2]

100 项与乳腺癌肝脏转移相关的临床结果

登录后查看更多信息

100 项与乳腺癌肝脏转移相关的转化医学

登录后查看更多信息

0 项与乳腺癌肝脏转移相关的专利（医药）

登录后查看更多信息

项与乳腺癌肝脏转移相关的文献（医药）

2023-06-01·Chemistry & biodiversity

Bee Venom Induces the Interaction between Phosphorylated Histone Variant, H2AX, and the Intracellular Site of beta-Actin in Liver and Breast Cancer Cells.

Article

作者: Çelik-Uzuner, Selcen ; Tetikoğlu, Sinan

Bee venom is a natural mixture and candidate anti-cancer agent with selective cytotoxic effect on some cancer cells. However, the cellular mechanisms of how bee venom selectively targets cancer cells remain elusive. The aim of this study was to reveal the genotoxic effect of bee venom in concordance with the location of β-actin protein throughout the nucleus or/and cytoplasm. For this aim, the level of H2AX phosphorylation (γH2AX) and intracellular location of β-actin were assessed by immunofluorescence in liver (HEPG2) and metastatic breast (MDA-MB-231) cancer cell lines compared to normal fibroblasts (NIH3T3) after bee venom treatment. Colocalisation profiles of γH2AX and β-actin in each cell line were also analysed. The results showed that the levels of γH2AX staining decreased in normal cells but increased in cancer cells. The majority of β-actin was localised within the cytoplasm of normal cells after bee venom treatment, but it was mostly accumulated within the nucleus in cancer cells. Colocalisation of β-actin and γH2AX both in nucleus and cytoplasm was induced in each cancer cell by different patterns. The results showed that normal and cancerous cells had different responses against bee venom, and suggested that bee venom induced a cellular response by the interaction between γH2AX and β-actin.

2023-06-01·Cellular Oncology

Ezrin accelerates breast cancer liver metastasis through promoting furin-like convertase-mediated cleavage of Notch1

Article

作者: Lash, Gendie E ; Chen, Miaojuan ; Lu, Qinsheng ; Hou, Huomei ; Liu, Hanbo ; Duan, Yaoyun ; Gan, Xiaowen ; Lu, Shenjiao ; Tian, Yun ; Pan, Yue ; Zhang, Min ; Ning, Fen

BACKGROUNDEzrin, known as a crosslinker between the plasma membrane and actin cytoskeleton, is closely associated with breast cancer (BC) progression. Here, we explored a novel role of ezrin in breast cancer liver metastasis (BCLM).METHODSThe clinical relevance of ezrin was evaluated using in silico tools and confirmed in BC specimens. The effect of ezrin on proliferation, migration and invasion was examined in vitro and in vivo using murine primary liver-metastatic breast cancer cells (mLM). The molecular mechanism involved in ezrin-mediated activation of the Notch1 signaling pathway was elucidated using in vitro models.RESULTSData-mining demonstrated that ezrin mRNA and protein expression is up-regulated in breast cancer cohorts and has prognostic significance. Ezrin overexpression promotes cell proliferation, migration and invasion in vitro and in vivo. Hairy and enhancer of split-1 (Hes1) is one of the most significantly enriched candidates of differentially expressed genes in ezrin overexpression and control mLM cells. Ezrin can positively regulate Hes1 mRNA and protein expression, and their coexpression was associated with poor prognosis in BC patients. Ezrin promoted BC cell proliferation in a Hes1-dependent manner without directly interacting with Hes1. The functional link between ezrin and Hes1 is dependent on Notch1 activation through promotion of furin-like convertase cleavage.CONCLUSIONOur results demonstrated that ezrin drives BCLM through activation of the Notch signaling pathway via furin-like convertase. These findings provide a better understanding of the mechanism of ezrin in breast cancer progression, with the goal of discovering a novel target for the treatment of BCLM in the future.

2022-04-01·Drug Development Research3区 · 医学

Design, synthesis, biological evaluation, and molecular docking of new benzofuran and indole derivatives as tubulin polymerization inhibitors

3区 · 医学

Article

作者: Awad, Hanem M. ; Ewies, Ewies F. ; El‐Sayed, Naglaa F. ; Fouad, Marwa A. ; El‐Hussieny, Marwa ; El Shehry, Mohamed F.

AbstractMicrotubules and the mitotic spindle have become an important target for cancer treatment due to their critical role in cell division. In this work, a novel series of benzofuran and indole derivatives were designed and synthesized, to be evaluated as tubulin polymerization inhibitors. 2‐Acetylbenzofuran derivatives 1a,b and 3‐acetylindole 1c were condensed with Wittig reagents 2a–d and Wittig‐Horner reagents 3a–e to afford the respective 2‐ethylidene derivatives 5a–j and 7a–e. Also, iminomethylene triphenylphosphine (2e) reacted with 1a,b to afford benzofuran‐2‐ylethylidene aniline derivatives 6a,b. In addition, compounds 1a,b reacted with trialkylphosphites 4a–c to give 1:1 adduct for which the Oxaphospholo[4,3‐b]benzofuran‐7‐yl)diazene derivatives 8a–f, were assigned. The possible reactions mechanisms were discussed and structural reasoning for the new compounds were based upon spectroscopic data. Their antiproliferative activities against two cell lines namely, HepG2 and MCF7 cells were then evaluated. It was found that the benzofuran compounds 5b, 6a, and 8c exhibited the strongest antiproliferative activities against both cell lines compared to doxorubicin. By studying the mechanism of action, compound 6a showed good inhibition of tubulin polymerization which leads to mitotic spindle formation disruption, cell cycle arrest in the G2/M phase, and apoptosis of HepG2 cells. A conducted docking study confirmed the in vitro results indicating that compound 6a fitted properly at the colchicine binding site of tubulin. Based on these findings, compound 6a can be considered as a promising anticancer candidate that can be subjected for further development as a tubulin polymerization inhibitor for treating liver and breast cell carcinoma.

项与乳腺癌肝脏转移相关的新闻（医药）

2024-09-27

·Pharma CMC

荣昌生物「维迪西妥单抗」拟纳入优先审评，治疗乳腺癌

9月25日，CDE官网显示，荣昌生物的注射用维迪西妥单抗拟纳入优先审评，拟定适应症为：用于既往接受过曲妥珠单抗或其生物类似物和紫杉类药物治疗的HER2阳性（HER2免疫组织化学检查结果为3+或FISH+）存在肝转移的晚期乳腺癌患者。今年6月，荣昌生物宣布维迪西妥单抗(商品名：爱地希®)治疗HER2阳性存在肝转移的晚期乳腺癌患者的Ⅲ期临床取得阳性结果，达到主要研究终点。这是一项在中国开展的、开放、平行对照、多中心的Ⅲ期临床研究（RC48-C006，NCT03500380），旨在评价注射用维迪西妥单抗对比拉帕替尼联合卡培他滨用于治疗HER2阳性晚期乳腺癌患者的有效性及安全性。根据本研究最终分析结果显示，与拉帕替尼联合卡培他滨相比，注射用维迪西妥单抗可显著延长患者的无进展生存期(PFS)。注射用维迪西妥单抗安全性数据与已知风险相似，未发现新的安全性信号。此前，维迪西妥单抗已在国内获批两项适应症，分别为二线尿路上皮癌和三线胃癌。内容来源于网络，如有侵权，请联系删除。